Hemolytic Disease of the Fetus and Newborn (HDFN) occurs when maternal IgG antibodies cross the placenta and destroy fetal red blood cells. Once one of the leading causes of perinatal death, it has been transformed by anti-D prophylaxis and modern fetal medicine—yet it remains a serious condition that demands vigilant screening, monitoring, and a coordinated multidisciplinary response.
HDFN (also called haemolytic disease of the newborn, HDN, or—when caused by anti-D—Rh disease) is a condition in which a pregnant person's immune system produces IgG antibodies directed against antigens on the fetus's red blood cells. Because IgG antibodies cross the placenta, they reach the fetal circulation and bind to fetal red cells, marking them for destruction. The result is fetal anemia of variable severity, and after birth, rapidly rising bilirubin that the newborn's immature liver cannot clear.
The antigens involved are inherited by the fetus from the biological father and are absent from the mother's own red cells. This is why HDFN is fundamentally a problem of incompatibility: the mother is exposed to a "foreign" red cell antigen, mounts an antibody response, and that antibody then acts against any current or future fetus carrying the antigen.
Understanding HDFN means following a sequence of events that begins with maternal exposure and ends with the clinical picture seen in the fetus and newborn.
The mother is first exposed to a red cell antigen she lacks—usually through a small fetomaternal haemorrhage during a previous pregnancy or delivery, or occasionally through a prior transfusion. Her immune system produces antibodies. The initial (primary) response is typically weak and IgM-dominant, which is why the sensitizing pregnancy is often unaffected. On re-exposure in a subsequent pregnancy, a brisk anamnestic response produces high-titre IgG.
IgG is actively transported across the placenta via the neonatal Fc receptor (FcRn), increasing substantially through the second and third trimesters. Once in the fetal circulation, the antibody binds fetal red cells carrying the target antigen.
Antibody-coated fetal red cells are removed by macrophages in the fetal spleen (extravascular haemolysis). As red cells are destroyed faster than they can be replaced, the fetus becomes anemic and the bone marrow and extramedullary sites (liver, spleen) ramp up red cell production.
Anti-K (anti-Kell) causes anemia not only by destroying mature red cells but by suppressing erythropoiesis—it targets Kell-bearing erythroid precursors in the marrow. Because there is less haemolysis, amniotic fluid bilirubin and reticulocyte responses underestimate severity. For this reason, anti-K pregnancies are monitored by titre and MCA Doppler rather than bilirubin-based methods, and intervention is considered at lower titres than for anti-D.
In severe disease, profound anemia leads to high-output cardiac failure, hepatic dysfunction with reduced albumin production, and increased capillary permeability. Fluid accumulates in two or more fetal compartments—skin oedema, ascites, pleural and pericardial effusions—a state called hydrops fetalis. Untreated, it is frequently fatal.
Before birth, the haemolysis-derived bilirubin is cleared by the placenta and the maternal liver, so even severely affected fetuses are not jaundiced in utero. After delivery that route is lost, and the newborn's immature, low-capacity liver cannot conjugate the bilirubin load. Unconjugated bilirubin rises quickly, and because it is fat-soluble it can cross the blood–brain barrier.
Very high unconjugated bilirubin can deposit in the basal ganglia and brainstem nuclei, causing acute bilirubin encephalopathy and, if untreated, permanent kernicterus—a syndrome of choreoathetoid cerebral palsy, sensorineural hearing loss, and gaze abnormalities. Preventing kernicterus is the central goal of postnatal management.
Any IgG red cell alloantibody directed at an antigen the fetus has inherited can, in principle, cause HDFN. In practice a handful account for the great majority of clinically significant disease.
| Antibody | Typical Severity | Notes |
|---|---|---|
| Anti-D | Mild to severe | Historically the dominant cause of severe HDFN; now largely preventable with anti-D immunoglobulin |
| Anti-c | Mild to severe | The most clinically important non-D Rh antibody; can cause severe disease |
| Anti-K (Kell) | Can be severe | Causes anemia mainly by suppressing erythropoiesis; severity poorly predicted by titre alone |
| Anti-E | Usually mild | Common in screening; severe disease is uncommon but reported |
| Anti-C, anti-e | Usually mild | Less frequently implicated in severe disease |
| Anti-Fya, anti-Jka, anti-S/s | Variable | Other clinically significant IgG antibodies that can occasionally cause HDFN |
| ABO (anti-A,B) | Usually mild | Most common cause overall; typically a group O mother with a group A or B infant; can affect a first pregnancy |
Maternal alloimmunization requires exposure to incompatible red cells. The common routes are:
These "potentially sensitizing events" are precisely the situations in which anti-D immunoglobulin is given to D-negative women carrying a potentially D-positive fetus (see Prevention).
HDFN ranges from a biochemical curiosity to a life-threatening emergency:
Management begins at the booking visit and intensifies if a clinically significant antibody is detected.
All pregnant women have ABO/D typing and an antibody screen at booking, usually repeated at around 28 weeks. If a clinically significant antibody is found, it is identified and quantified (by titre, or in some countries by quantification in IU/mL for anti-D and anti-c).
Knowing whether the fetus actually carries the target antigen focuses monitoring and avoids unnecessary intervention:
The peak systolic velocity in the fetal middle cerebral artery rises as anemia lowers blood viscosity and increases cardiac output. An MCA-PSV above 1.5 multiples of the median (MoM) predicts moderate-to-severe fetal anemia with high sensitivity, and has largely replaced serial amniocentesis (Liley/Queenan amniotic bilirubin curves) for non-invasive surveillance.
When fetal anemia is significant and the fetus is too premature for safe delivery, red cells are transfused directly to the fetus—most commonly into the umbilical vein at the cord insertion (intravascular transfusion), guided by ultrasound. The blood is group O, D-negative (or antigen-negative for the relevant antibody), irradiated, CMV-safe, fresh, and tightly packed. IUTs are repeated as needed until delivery is appropriate. The procedure carries real risks and is performed in specialist fetal medicine centres.
Delivery is planned to balance the risks of ongoing intrauterine disease against those of prematurity, typically in a unit with neonatal intensive care and transfusion support immediately available.
Care after birth focuses on treating anemia, controlling bilirubin to prevent kernicterus, and watching for late anemia.
The single greatest advance in this field is the prevention of D alloimmunization with anti-D immunoglobulin (RhIg). By binding and clearing fetal D-positive cells from the maternal circulation before the mother can mount her own response, RhIg prevents sensitization.
Dosing conventions differ internationally—for example, UK (BCSH/NICE) protocols are commonly expressed in international units (e.g. a minimum of 500 IU postnatally, with additional doses guided by FMH quantification), while US protocols are commonly expressed in micrograms (e.g. 300 μg / 1500 IU). Cell-free fetal RHD typing is increasingly used to target antenatal prophylaxis only to women carrying a D-positive fetus, sparing those whose fetus is D-negative. Always follow your local guideline and product information.
For women who are already immunized, RhIg has no role—prevention has passed, and the focus shifts entirely to the monitoring and treatment pathways described above. This is why screening, accurate antibody identification, and pre-pregnancy counselling for previously affected women matter so much.
HDFN is a story of remarkable progress: a condition that once caused widespread perinatal loss is now, in the case of Rh disease, largely preventable, and even severe disease is frequently survivable thanks to non-invasive surveillance and intrauterine therapy. The remaining burden falls increasingly on non-D antibodies and on women who are already immunized—making robust antenatal screening, accurate antibody identification, and specialist multidisciplinary care as important as ever.
↑ Back to Top